MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) announced Wednesday that New York State Medicaid will begin covering transcranial magnetic stimulation (TMS) for adults with major depressive disorder (MDD), a move expected to expand access to thousands of patients who have not responded to traditional treatments.
Coverage will take effect October 1, 2025, for fee-for-service Medicaid members and November 1, 2025, for those enrolled in Medicaid Managed Care Plans. The decision extends eligibility to nearly one million fee-for-service members and more than 4.4 million managed care enrollees.
“This decision by New York State Medicaid reflects the growing recognition of TMS as an evidence-based, life-changing treatment for patients with depression,” said Keith J. Sullivan, president and CEO of Neuronetics. “We commend the state for making TMS more accessible to patients who need it most, and we remain committed to working alongside providers and policymakers to expand access nationwide.”
MDD affects an estimated 21 million U.S. adults each year. Roughly 6.4 million do not tolerate or fail to respond to antidepressant medications. NeuroStar® Advanced Therapy, Neuronetics’ flagship TMS device, delivers targeted magnetic pulses to stimulate brain regions involved in mood regulation. Clinical outcomes from the company’s database show response rates as high as 83% and remission rates of 62%.
The inclusion of TMS under New York’s Medicaid program highlights the increasing acceptance of non-drug, non-invasive therapies in addressing persistent mental health needs. It also marks a significant step for Neuronetics, which has been working to expand insurance coverage for its treatment nationwide.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.